drugset / Trial / NCT00631722

Multicenter, Open-Label, Randomised, Haloperidol-controlled Study to Evaluate Seroquel as Mono-Therapy in the Treatment of Agitated Symptoms in the Patients With Acute Episode of Schizophrenia

NCT00631722

Completed 80 enrolled Peking University
RandomizedParallel-groupOpen-labelTreatment

Summary

This study attempts to observe the efficacy (response time) and safety of the second-generation antipsychotic agent-quetiapine versus the first-generation antipsychotic agent-haloperidol, in treating acute schizophrenia episode and to evaluate the effect of the effectiveness of acute schizophrenia episode on long-term tolerability.

Timeline

Start
2007-05
Primary completion
2008-01
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Haloperidol Other / unclassified 12 mg
Comparator Haloperidol Other / unclassified 20 mg
Subject Quetiapine Small molecule 600 mg
Subject Quetiapine Small molecule 750 mg

Indications